EP2056812A1 - Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases - Google Patents

Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Info

Publication number
EP2056812A1
EP2056812A1 EP06802881A EP06802881A EP2056812A1 EP 2056812 A1 EP2056812 A1 EP 2056812A1 EP 06802881 A EP06802881 A EP 06802881A EP 06802881 A EP06802881 A EP 06802881A EP 2056812 A1 EP2056812 A1 EP 2056812A1
Authority
EP
European Patent Office
Prior art keywords
composition
colchicine
individual
nab
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06802881A
Other languages
German (de)
English (en)
French (fr)
Inventor
Neil P. Desai
Vuong Trieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of EP2056812A1 publication Critical patent/EP2056812A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This application pertains to methods of inhibiting angiogenesis and treating angiogenesis-associated diseases. Specifically, the application pertains to methods of inhibiting angiogenesis and treating angiogenesis-associated diseases by administering an effective amount of a composition comprising a colchicine or thiocolchicine dimer.
  • Angiogenesis is a highly regulated biological process by which new blood vessels are formed. Uncontrolled angiogenesis leads to many diseases.
  • age-related macular degeneration AMD
  • AMD age-related macular degeneration
  • Another disease in which angiogenesis is implicated is rheumatoid arthritis, where blood vessels in the synovial lining of the joints undergo angiogenesis.
  • the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction.
  • Uncontrolled angiogenesis is also associated with diseases such as diabetic retinopathy, psoriasis, restenosis, and neovascular glaucoma.
  • angiogenesis is also involved in tumor formation and metastasis.
  • tumors which enlarge to greater than about two millimeters in diameter must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. After these new blood vessels become embedded in the tumor, they provide nutrients and growth factors essential for tumor growth and facilitate metastasis of tumor cells.
  • VTAs vascular Targeting Agents
  • Thiocolchicine dimers are hydrophobic compounds that have been previously described. See, e.g., U.S. Pat. No. 6,627,774. These compounds have dual mechanisms of action, i.e., the compounds have both anti-microtubule activities and topoisomerase I inhibitory activities. Raspaglio et al., Biochem. Pharmacol. 2005, 69(1): 113-21. Nanoparticle albumin-bound formulations of thiocolchicine dimers Nab- 5404 and Nab-5676 have been developed as cytotoxic chemotherapeutic agents for treating cancer. See, for example, Bernacki et al., Proc. Amer. Assoc.
  • the invention in one aspect provides a method of inhibiting angiogenesis in an individual, comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer (such as IDN5404), wherein the composition is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a composition comprising a colchicine or thiocolchicine dimer (such as IDN5404), wherein the composition is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of a composition comprising a colchicine or thiocolchicine dimer (such as IDN5404), wherein the amount of the colchicine or thiocolchicine dimer (such as IDN5404) in the composition (i.e., the amount per administration) is less than about any of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mg/m 2 body surface.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of a composition comprising a colchicine or thiocolchicine dimer (such as IDN5404), wherein the amount of the colchicine or thiocolchicine dimer (such as IDN5404) in the composition is less than about any of 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, or 0.6 mg/kg.
  • the composition is administered at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily.
  • the composition is administered (with or without breaks) for at least about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more month(s). In some embodiments, the composition is administered via any of intravenous, intraocular, intraarterial, oral, topical, or inhalational routes.
  • compositions used in methods described herein may further comprise a biocompatible polymer, such as a carrier protein.
  • a biocompatible polymer such as a carrier protein.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual a composition comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the composition is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of a composition comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the amount of the colchicine or thiocolchicine dimer (such as IDN5404) in the composition is less than about any of 2, 3, 4,
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of a composition comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the amount of the colchicine or thiocolchicine dimer (such as IDN5404) in the composition is less than about any of 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, or 0.6 mg/kg.
  • the carrier protein-containing composition is substantially free (such as free) of surfactant.
  • the composition is administered at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily. In some embodiments, the composition is administered (with or without breaks) for at least about any of 1, 2, 3, 4, 5,
  • compositions used in methods described herein may comprise particles
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual a composition comprising nanoparticles comprising a carrier protein (such as albumin) and a colchicine or thiocolchine dimer (such as IDN5404), wherein the composition is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a composition comprising nanoparticles comprising a carrier protein (such as albumin) and a colchicine or thiocolchine dimer (such as IDN5404), wherein the composition is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the amount of the colchicine or thiocolchicine dimer (such as IDN5404) in the composition is less than about any of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mg/m 2 body surface.
  • a carrier protein such as albumin
  • a colchicine or thiocolchicine dimer such as IDN5404
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the amount of the colchicine or thiocolchicine dimer (such as IDN5404) in the composition is less than about any of 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, or 0.6 mg/kg.
  • a carrier protein such as albumin
  • a colchicine or thiocolchicine dimer such as IDN5404
  • the composition is administered at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily. In some embodiments, the composition is administered (with or without breaks) for at least about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more month(s). In some embodiments, the composition is administered via any of intravenous, intraocular, intraarterial , oral, topical, or inhalational routes.
  • the particles in the composition have an average diameter of no greater than about 200 nm. In some embodiments, the particle-containing composition is substantially free (such as free) of surfactant. In some embodiments, the weight ratio of the protein (such as albumin) to the colchicine or thiocolchicine dimer in the composition is about 18:1 or less, such as about 9:1 or less. In some embodiments, the colchicine or thiocolchicine dimer is coated with the carrier protein (such as albumin). In some embodiments, the particles in the composition have an average diameter of no greater than about 200 nm and the composition is substantially free (such as free) of surfactant.
  • the weight ratio of the protein (such as albumin) to the colchicine or thiocolchicine dimer in the composition is about 18:1 or less, such as about 9:1 or less.
  • the colchicine or thiocolchicine dimer is coated with the carrier protein (such as albumin).
  • the particles in the composition have an average diameter of no greater than about 200
  • the particles (particularly nanoparticles) in the composition have an average diameter of no greater than about 200 nm and the colchicine or thiocolchine dimer is coated with protein (such as albumin). Other combinations of the above characteristics are also contemplated.
  • the particle composition is Nab-5404. Particle compositions comprising other colchicine or thiocolchicine dimers may also comprise one or more of the above characteristics.
  • colchicine or thiocolchicine dimers described herein comprise two
  • the colchicine or thiocolchicine dimer comprises at least one thiocolchicine subunit. In some embodiments, the colchicine or thiocolchicine dimer comprises two thiocolchicine subunits. In some embodiments, the colchicine or thiocolchicine dimer is a compound of formula (I):
  • each subunit is either a methoxy or a methylthio group
  • R 2 is methoxy, hydroxyl, or methylenedioxy when taken together with R 3
  • R 3 is methoxy, hydroxyl, or methylenedioxy when taken together with R 2
  • X is a linking group.
  • X contains at least one carbon atom.
  • the colchicine or thiocolchicine dimer has is a compound of formula (II):
  • B 1 is a methoxy or a methylthio group
  • B 2 is a methoxy or a methylthio group
  • n is an integer from 0 to 8
  • Y is a CH 2 group or, when n is 1, can also be a group of formula NH.
  • n is any of (such as selected from the group consisting of) 0, 1, 2, 3, 4, 5, 6, 7, or 8.
  • n is 1.
  • n is 1 and Y is NH.
  • n is 2.
  • both B 1 and B 2 are methoxy groups.
  • both B 1 and B 2 are methylthio groups.
  • B 1 is a methoxy group and B 2 is a methylthio group. In some embodiments, B 1 is a methylthio group and B 2 is a methoxy group.
  • the colchicine or thiocolchicine dimer is any of (and in some embodiments selected from the group consisting of): IDN5404, IDN5676, IDN5800, and IDN5801. In some embodiments, the colchicine or thiocolchicine dimer is IDN5404. In some embodiments, the colchicine or thiocolchicine dimer is IDN5676.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual a composition comprising nanoparticles comprising albumin and any of IDN5404, IDN5676, IDN5800, and IDN5801 (hereinafter designated as "N ⁇ -5404,” “Nab-5676,” 'W ⁇ -5800” and “JV ⁇ -5801,” respectively).
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual Nab-5404 (or any of Nab-5676, Nab-5800, and Nab-5801), wherein the Nab-5404 (or any of Nab-5676, Nab-5800, and Nab-5801) is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of Nab-5404 (or any of Nab-5676, Nab-5800, and JV ⁇ -5801) is insufficient to induce significant cytotoxicity in the individual.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of Nab-5404 (or any ofNab-5676, Nab-5800, and Nab- 5801), wherein the amount of Nab-5404 (or any ofNab-5676, Nab-5800, and Nab-5801) is less than about any of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mg/m 2 body surface.
  • a method of inhibiting angiogenesis in an individual comprising administering to the individual an effective amount of Nab-5404 (or any of Nab-5676, Nab-5800, and iV ⁇ -5801), wherein the amount of Nab-5404 (or any of Nab- 5676, Nab-5800, and Nab-5801) is less than about any of 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, or 0.6 mg/kg.
  • the composition is administered at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily.
  • the composition is administered (with or without breaks) for at least about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more month(s). In some embodiments, the composition is administered via any of intravenous, intraocular, intraarterial , oral, topical, or inhalational routes.
  • the angiogenesis-associated disease is a non- tumorous angiogenesis-associated disease, including for example eye diseases (such as macular degeneration, diabetic retinopathy, or neovascular glaucoma), cardiovascular diseases (such as restenosis and atherosclerosis), skin diseases (such as psoriasis), and arthritis (such as rheumatic arthritis).
  • eye diseases such as macular degeneration, diabetic retinopathy, or neovascular glaucoma
  • cardiovascular diseases such as restenosis and atherosclerosis
  • skin diseases such as psoriasis
  • arthritis such as rheumatic arthritis
  • a method of treating a non-tumorous angiogenesis-associated disease in an individual comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating the non-tumorous angiogenesis- associated disease.
  • the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of treating a non-tumorous angiogenesis-associated disease in an individual comprising administering to the individual a composition comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the composition is in an amount that is effective in treating the non-tumorous angiogenesis- associated disease in an individual.
  • the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of treating a non-tumorous angiogenesis-associated disease in an individual comprising administering to the individual a composition comprising particles (such as nanoparticles) comprising a carrier protein (such as albumin) and a colchicine or thiocolchine dimer (such as IDN5404), wherein the composition is in an amount that is effective in treating the non-tumorous angiogenesis-associated disease.
  • the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of treating a non-tumorous angiogenesis-associated disease in an individual comprising administering to the individual Nab-5404 (or Nab-5676, Nab-5800, or JV ⁇ -5801), wherein the Nab-5404 (or Nab-5676, Nab-5800, or JV ⁇ -5801) is in an amount that is effective in treating the non- tumorous angiogenesis-associated disease.
  • the amount of Nab-5404 (or Nab-5676, Nab-5%00, or Nab-5801) is insufficient to induce significant cytotoxicity in the individual.
  • the angiogenesis-associated disease is a tumor- related disease, including for example cancer and benign tumor.
  • Cancers that can be treated by methods described herein include, but are not limited to, breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma, Kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, melanoma, ovarian cancer, mesothelioma, gliomas, glioblastomas, neuroblastomas, and multiple myeloma.
  • the cancer is a solid tumor (such as metastatic solid tumor). By way of example, methods of treating cancer are further described below.
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of the colchicine or thiocolchicine dimer in the composition is less than about any of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 11%, 12%, 13%, 14%, or 15% of the corresponding maximum tolerated dose ("MTD”) of the colchicine or thiocolchicine dimer.
  • MTD maximum tolerated dose
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a carrier protein such as albumin
  • thiocolchicine dimer such as IDN5404
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer (such as IDN5404), wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of the colchicine or thiocolchicine dimer in the composition is less than about any of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 11%, 12%, 13%, 14%, or 15% of the corresponding MTD of the colchicine or thiocolchicine dimer.
  • a carrier protein such as albumin
  • a colchicine or thiocolchicine dimer such as IDN5404
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising particles (such as nanoparticles) comprising a carrier protein (such as albumin) and a colchicine or thiocolchine dimer (such as IDN5404), wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a composition comprising particles (such as nanoparticles) comprising a carrier protein (such as albumin) and a colchicine or thiocolchine dimer (such as IDN5404), wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising particles (such as nanoparticles) comprising a carrier protein (such as albumin) and a colchicine or thiocolchine dimer (such as IDN5404), and wherein the amount of the colchicine or thiocolchicine dimer in the composition is less than about any of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 11%, 12%, 13%, 14%, or 15% of the corresponding MTD of the colchicine or thiocolchicine dimer.
  • particles such as nanoparticles
  • a carrier protein such as albumin
  • a colchicine or thiocolchine dimer such as IDN5404
  • a method of treating cancer in an individual comprising administering to the individual Nab-5404 (or Nab-5676, Nab-5800, or Nab- 5801), wherein the JV ⁇ -5404 (or Nab-5676, Nab-5800, or NabSSOl) is in an amount that is effective in treating cancer, and wherein the amount of Nab-5404 (or Nab-5676, Nab- 5800, or Nab-5801) is insufficient to induce significant cytotoxicity in the individual.
  • a method of treating cancer in an individual comprising administering to the individual Nab-5404 (or Nab-5676, Nab-5800, or Nab- 5801), wherein the Nab-5404 (or Nab-5676, Nab-5800, or Nab-5801) is in an amount that is effective in treating cancer, and wherein the amount of Nab-5404 (or Nab-5676, Nab- 5800, or Nab-5801) is less than about any of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 11%, 12%, 13%, 14%, or 15% of the corresponding MTD of Nab-5404 (ox Nab-5676, Nab-5800, orNab-5801).
  • compositions, unit dosages, ldts, and articles of manufacture that are useful for methods described herein.
  • Figure IA shows the effect of Nab-5404 on microtubule formation using
  • Figure IB shows the effect ofNab-5676 on microtubule formation using MX-I breast carcinoma cells.
  • Figures 2A-2C show micrographs of stained microtubule network in MX-I cells after treatment with control vehicle (PBS, 2A), 0.6 ⁇ g/ml Nab-5404 (2B), and ⁇ g/ml Nab-5676 (2C).
  • Figure 3 shows the anti-angiogenenic activity of Nab-5404, Nab-5676 and
  • FIGS. 3A-3D provide micrographs of tubule formation after treatment with control vehicle (3C), 0.01 ⁇ g/ml Nab-5404 (3A), 0.01 ⁇ g/ml Nab-5676 (3B), and 0.01 ⁇ g/ml CA4P (3D).
  • Figure 4 shows a comparison of the tubule length for cells treated with Nab-
  • Figure 5 shows the anti-angiogenenic activity of Nab-5404 and Nab-5676 as evaluated by microvessel/tubule formation or disruption. Cells were incubated with various compounds on day 8 and stained on day 11.
  • Figures 5A-5C provide micrographs of tubule formation after treatment with control vehicle (5A), 0.01 ⁇ g/ml Nab-5404 (5B), and 0.01 ⁇ g/ml Nab-5676 (5C).
  • Figure 4D shows a comparison of the tubule length for cells treated with Nab-5404 and Nab-5676 across a concentration range of 0.0 to 10 ⁇ g/ml.
  • Figure 6 shows the anti-angiogenenic activity of Nab-5404 as evaluated by microvessel/tubule formation or disruption. Cells were incubated with various concentrations of the compound on day 11 and stained on day 12.
  • Figures 6 A to 6F provide micrographs of tubule formation and disruption after treatment with control vehicle (6A), 0.001 ⁇ g/ml iV ⁇ -5404 (6B), 0.01 ⁇ g/ml Nab-5404 (6C) 5 0.1 ⁇ g/ml Nab-5404 (6D), 1 ⁇ g/ml Nab-5404 (6E), and 10.0 ⁇ g/ml Nab-5404 (6F).
  • Figure 7 shows the anti-angiogenenic activity of Nab-5676 as evaluated by microvessel/tubule formation or disruption. Cells were incubated with various concentrations of the compound on day 11 and stained on day 12.
  • Figures 7A to 7F show micrographs of tubule formation and disruption after treatment with control vehicle (7A), 0.001 ⁇ g/ml Nab-5676 (7B), 0.01 ⁇ g/ml Nab-5676 (7C), 0.1 ⁇ g/ml Nab-5676 (7D), 1 ⁇ g/ml Nab-5676 (7E), and 10.0 ⁇ g/ml Nab-5676 (7F).
  • Figure 8 shows the anti-angiogenenic activity of CA4P as evaluated by microvessel/tubule formation or disruption. Cells were incubated with various concentrations of the compound on day 11 and stained on day 12. Figures 8A to 8C show micrographs of tubule formation and disruption after treatment with 0.01, 0.1, and 1.0 ⁇ g/ml CA4P, respectively.
  • Figure 9 shows a comparison of the anti-angiogenenic activities of Nab-
  • Figure 10 shows the effects of Nab-5404 on HT-29 tumor growth in a xenograft murine model using a 2 cycle, low-dose/high dose schedule.
  • First cycle doses were 1.7, 2.5 or 3.4 mg/kg, days 0-14; second cycle doses were 20, 30, or 40 mg/kg, days 15-30.
  • Figure 1OB shows the mean percent weight loss of the mice over days 0 to 40.
  • Figure 11 shows the effects of Nab-5676 on HT-29 tumor growth in a xenograft murine model using a 2 cycle, low-dose/high dose schedule.
  • First cycle doses were 1.7, 2.5 or 3.4 mg/kg, days 0-14; second cycle doses were 20, 30, or 40 mg/kg, days 15-30.
  • Figure 1 IB shows the mean percent weight loss of the mice over days 0 to 40.
  • Figure 12 shows the effects of CA4P on HT-29 tumor growth in a xenograft murine model. HT-29 tumors were treated with 100 mg/kg after they had reached a volume of 900 mm3.
  • compositions comprising a thiocolchicine dimer, specifically, albumin-containing nanoparticle formulations of thiocolchicine dimer, more specifically, albumin-containing nanoparticle formulations of IDN-5404 ("Nab-5404") and albumin-containing nanoparticle formulations of IDN-5676 ( ⁇ W ⁇ Z> ⁇ 5676”), are effective in inhibiting microvessel formation and disrupt established microvessels in vitro.
  • a thiocolchicine dimer specifically, albumin-containing nanoparticle formulations of thiocolchicine dimer, more specifically, albumin-containing nanoparticle formulations of IDN-5404 ("Nab-5404") and albumin-containing nanoparticle formulations of IDN-5676 ( ⁇ W ⁇ Z> ⁇ 5676”)
  • the IC50 values for these activities are significantly lower than those required for in vitro cytotoxicity activities of the compositions.
  • compositions comprising a thiocolchicine dimer are effective in preventing tumor growth in vivo at a dose that is significantly lower than the corresponding maximum tolerated dose (MTD) of the compositions.
  • MTD maximum tolerated dose
  • an effective and noncytotoxic amount is also advantageous for treating cancer.
  • Traditional chemotherapy with a cytotoxic agent is typically carried out at a dose that is either the same or close to the maximum tolerated dose of the agent in order to maximize the cytotoxic effect of the agent.
  • This high-dose schedule requires an extended treatment-free period to allow recovery of normal host cells. In the meantime, tumor cells may also resume growth during the treatment free period. This could increase the risk of the developing drug resistant tumor cells.
  • a noncytotoxic dose i.e., amount
  • a colchicine or thiocolchicine dimer allows treatment without significant breaks in the treatment cycle, thus reduces the risk of developing drug resistance. Furthermore, a noncytotoxic dose minimizes the possibility of developing apparent systemic toxicity (such as weight loss) and side effects induced by the drag.
  • the invention in one aspect provides a method of inhibiting angiogenesis (including targeting established vascularization) in an individual, comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • the method comprises administering to the individual a composition comprising a carrier protein (such as albumin) and a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in inhibiting angiogenesis, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • the invention provides a method of treating a non- tumorous angiogenesis-associated disease in an individual, comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating the non-tumorous angiogenesis- associated disease.
  • the method comprises administering to the individual a composition comprising a carrier protein and a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating the non- tumorous angiogenesis-associated disease.
  • the invention provides a method of treating a tumor- related disease in an individual, comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating the tumor-related disease, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • the method comprises administering to the individual a composition comprising a carrier protein and a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of the composition is insufficient to induce significant cytotoxicity in the individual.
  • compositions are useful for methods described herein.
  • compositions include and is applicable to compositions of the invention.
  • compositions also provides pharmaceutical compositions comprising the components described herein.
  • the term "individual" is a mammal, including humans.
  • An individual includes, but is not limited to, human, bovine, equine, feline, canine, rodent, or primate.
  • the individual is human.
  • the individual is an experimental animal model for studying angiogenesis or angiogenesis-associated disease(s).
  • the disclosure includes all stereoisomers of the compounds referred to herein, including enantiomers and diastereomers. Unless stereochemistry is explicitly indicated in a structure, the disclosed structure is intended to embrace all possible stereochemical variants.
  • the disclosure includes all enantiomers of any chiral compound disclosed, in either substantially pure levorotatory or dextrorotatory form, or in a racemic mixture, or in any ratio of enantiomers.
  • the disclosure includes any diastereomers of the compounds referred to in the above formulas in substantially pure diastereomeric form and in the form of mixtures in all ratios.
  • the disclosure also includes all solvates of the compounds referred to herein, including all hydrates of the compounds referred to herein.
  • the disclosure also includes all polymorphs, including crystalline and non-crystalline forms of the compounds referred to herein.
  • the disclosure also includes all salts of the compounds referred to herein, particularly pharmaceutically-acceptable salts. Metabolites and prodrugs of the compounds disclosed herein are also embraced by the disclosure.
  • the disclosure also includes use of any or all of the stereochemical, enantiomeric, diastereomeric, solvates, hydrates, polymorphic, crystalline, non-crystalline, salt, pharmaceutically acceptable salt, metabolite and prodrug variations of the compounds as described.
  • the invention in one aspect provides a method of inhibiting angiogenesis in an individual by administering a composition (such as a carrier protein-containing composition) comprising colchicine or thiocolchicine dimer.
  • a composition such as a carrier protein-containing composition
  • the composition is in an amount that is effective in inhibiting angiogenesis.
  • the amount of the composition administered is, however, insufficient to induce significant cytotoxicity in the individual.
  • Angiogenesis used herein refers to the process of generating new blood vessels in a tissue or organ. Angiogenesis typically begins with the erosion of the basement membrane of a blood vessel by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane.
  • Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane.
  • the migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate.
  • the endothelial sprouts merge with each other to form capillary loops, creating the new vessel.
  • “Inhibiting angiogenesis” refers to reducing, impeding, or suppressing angiogenesis in one or more tissues in an individual, including for example eye tissue, cardiovascular tissue, skin tissue, arthritic tissue, and tumor tissue.
  • Inhibition of angiogenesis can be achieved by affecting one or more steps of the angiogenesis process, for example, by attenuating the migration and survival of activated endothelial cells, preventing "sprouting" of cells from parent vessel, and/or preventing formation of new blood vessels. Changes in microvessel density are also encompassed within the term “inhibiting angiogenesis.”
  • the term “inhibiting angiogenesis” also encompasses disrupting established vasculature.
  • “Disrupting established vasculature” refers to the ability to occlude, dissolve, or otherwise affect existing vasculature formed by angiogenesis. The disruption of the vasculature can be reversible or irreversible, partial or complete.
  • methods provided herein encompass one or more of the following aspects: inhibiting (such as reducing, impeding, or preventing) endothelial cell migration, inhibiting (such as reducing, impeding, or preventing) "sprouting" of endothelial cells from parent vessel, inhibiting (such as reducing, impeding, or preventing) formation of new blood vessels, and targeting (such as occluding, disrupting, or destroying) established vasculature formed by angiogenesis.
  • a method of inhibiting (such as reducing, impeding, or preventing) blood vessel formation in an individual is provided.
  • a method of disrupting such as occluding, dissolving, or otherwise affecting
  • a method of reducing density of microvessels in a tissue of an individual refers to an amount or dose of the composition which, upon single or multiple dose administration to the individual, provides a desired effect in the individual.
  • the composition is "in an amount that is effective in inhibiting angiogenesis” if the amount of the composition is sufficient to reduce, impede, or prevent angiogenesis (such as one or more aspects of angiogenesis) in one or more tissues in an individual.
  • an effective amount used in the treatment context refers to an amount of a compound or composition sufficient to treat a specified disorder, condition or disease such as ameliorate, palliate, lessen, and/or delay one or more of its symptoms.
  • An effective amount can be determined in vitro and/or vivo. Methods of determining an effective amount of a composition for inhibiting angiogenesis are known in the art.
  • the amount of the composition is effective in inhibiting angiogenesis in an eye tissue.
  • the amount of the composition is effective in inhibiting angiogenesis in a cardiovascular tissue.
  • the amount of the composition is effective in inhibiting angiogenesis in a skin tissue.
  • the amount of the composition is effective in inhibiting angiogenesis in an arthritic tissue. In some embodiments, the amount of the composition is effective in inhibiting angiogenesis in a tumor tissue. In some embodiments, the amount of the composition is effective in inhibiting new vessel formation. In some embodiments, the amount of the composition is effective in inhibiting "sprouting" of endothelial cells from parent blood vessel. In some embodiments, the amount of the composition is effective in inhibiting migration of endothelial cells. In some embodiments, the amount of the composition is effective to disrupt established vasculature.
  • the amount of the composition is effective in inhibiting angiogenesis (such as any one or more aspects of angiogenesis) by at least about any of 5%, 10%, 20%, 40%, 50%, or more.
  • a composition is "in an amount that is insufficient to induce significant cytotoxicity" (also referred to as "noncytotoxic amount”) if the amount of the composition is insufficient to allow the colchicine or thiocolchicine dimer to cause significant cell death in an individual. Cytotoxicity can be measured by one or more of the following. For example, noncytoxic amount can be determined based on an in vitro cell viability assay. The noncytotoxic amount can be an amount that is insufficient to cause about 50% or more cell death in an in vitro cell viability assay.
  • the amount of the composition is insufficient to cause about any of 40% or more, 30% or more, 20% or more, 10% or more, 5% or more, 4% or more, 3% or more, 2% or more, or 1% or more cell death in an in vitro cell viability assay. In some embodiments, the amount of the composition is insufficient to cause any measurable cell death in an in vitro cell viability assay.
  • Suitable cells for in vitro viability assays include, but are not limited to, tumor cells (such as MX-I breast carcinoma cell lines, HepG2 hepatoma cell lines, and HT-29 colon carcinoma cell lines) and normal cells (such as primary rat hepatocytes).
  • Noncytotoxic amount can also be determined based on in vivo assay of drug toxicity.
  • the noncytotoxic amount can be an amount that is insufficient to kill about 50% or more of the test population in in vivo cytotoxicity assays.
  • the amount of the colchicine or thiocolchicine dimer is insufficient to kill about any of 40% or more, 30% or more, 20% or more, 10% or more, 5% or more, 4% or more, 3% or more, 2% or more, or 1% or more test population in an in vivo cytotoxicity assay.
  • the amount of the composition is insufficient to cause any death in a test population in an in vivo drug toxicity assay.
  • Noncytotoxic amount can also be determined based on the amount of colchicine or thiocolchicine dimer that is required to induce apparent systemic toxicity (such as weight loss) in an individual, that is, the amount of the drug is noncytotoxic if it does not induce any apparent systemic toxicity.
  • a noncytotoxic amount is an amount that induces less than about 15% (including for example less than about any of 10%, 8%, 5%, or less) of weight loss.
  • the amount of the colchicine or thiocolchicine dimer in the composition at each administration is less than about any of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 mg/m 2 .
  • the amount of the colchicine or thiocolchicine dimer can range from about 0.25 mg/m 2 body surface to about 15 mg/m 2 , about 0.25 mg/m 2 to about 10 mg/m 2 , about 0.25 mg/m 2 to about 8 mg/m 2 , about 0.25 mg/m 2 to about 4 mg/m 2 , and about 0.25 mg/m 2 to about 2 mg/m 2 .
  • the amount of the colchicine or thiocolchicine dimer in the composition at each administration is less than about any of 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, or 0.6 mg/kg.
  • the amount of the colchicine or thiocolchicine dimer can range from about 0.05 mg/kg to about 0.5 mg/kg, about 0.08 mg/kg to about 0.3 mg/kg, and about 0.1 mg/kg to about 0.2 mg/mg.
  • the colchicine and thiocolchincine dimer is in an amount that does not induce drug resistance over an extended administration period (such as 6 months or more), with or without breaks.
  • the colchicine and thiocolchicine dimer is in an amount that does not induce significant side effects in the individual (such as side effects that typically accompany chemotherapy).
  • Side effects that typically accompany chemotherapy include, for example, dehydration, diarrhea, nausea, vomiting, vision loss or disturbance, and anemia.
  • Dosing frequency for the compositions includes, but is not limited to, at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily.
  • the interval between each administration is less than about a week, such as less than about any of 6, 5, 4, 3, 2, or 1 day(s).
  • the interval between each administration is constant.
  • the administration can be carried out daily, every two days, every three days, every four days, every five days, or weekly.
  • the administration can be carried out twice daily, three times daily, or more frequent.
  • the administration of the composition can be extended over an extended period of time, such as from about a month up to about three years.
  • the dosing regime can be extended over aperiod of any of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, and 36 months, hi some embodiments, there is no break in the dosing schedule.
  • the interval between each administration is no more than about a week.
  • composition described herein can be administered to an individual via any route in the art, including, but not limited to, intravenous, intraperitoneal, intraocular, intra-arterial, intrapulmonary, oral, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transdermal, transpleural, intraarterial, topical, inhalational (e.g., as mists of sprays), transmucosal (such as via nasal mucosa), subcutaneous, transdermal, gastrointestinal, intraarticular, intracisternal, intraventricular, rectal (i.e., via suppository), vaginal (i.e., via pessary), intracranial, intraurethral, intrahepatic, and intratumoral.
  • the composition is administered systemically.
  • the composition is administered locally.
  • the composition is administered via any of intravenous, intraocular, intraarterial , oral, topical, or
  • the composition can be administered directly to the eye or the eye tissue.
  • the composition can be administered topically to the eye, as in eye drops.
  • the composition can also be administered via injection to the eye or to the tissues associated with the eye.
  • the composition can be administered via intraocular injection, periocular injection, subretinal injection, intravetreal injection, trans-septal injection, subscleral injection, intrachoroidal injection, intracameral injection, subconjunctival injection, sub-Tenon's injection, retrobulbar injection, peribulbar injection, or posterior juxtascleral delivery.
  • the composition may be administered, for example, to the vitreous, aqueous humor, sclera, conjunctiva, the area between the sclera and conjunctiva, the retina choroids tissues, macula, or other area in or proximate to the eye of an individual.
  • exemplary periocular routes for retinal drug delivery see Periocular routes for retinal drug delivery, Raghava et al. (2004), Expert Opin. Drug Deliv, 1(1):99-114.
  • the composition can also be administered to the individual as an implant.
  • Preferred implants are biocompatible and/or biodegradable sustained release formulations which gradually release the compounds over a period of time. Ocular implants for drug delivery are well-known in the art.
  • composition can also be administered to the individual using iontophoresis, including, but not limited to, the ionophoretic methods described in U.S. Pat. No. 4,454,151 and U.S. Pat. App. Pub. Nos. 2003/0181531 and 2004/0058313.
  • Angiogenesis-associated disease refers to a disease or disorder where angiogenesis is one aspect of the disease.
  • the angiogenesis-associated disease may be caused by abnormal angiogenesis.
  • the angiogenesis-associated disease is mediated at least in part by angiogenesis.
  • angiogenesis is necessary for the development of the angiogenesis-associated disease.
  • Angiogenesis-associated diseases are known in the art, and include, for example, non- tumorous angiogenesis-associated diseases such as macular degeneration, diabetic retinopathy, rheumatoid arthritis, and other diseases described herein.
  • the angiogenesis-associated disease is a tumor-related disease, such as cancer or benign tumor.
  • treatment is an approach for obtaining beneficial or desired clinical results.
  • beneficial or desired clinical results include, but are not limited to, any one or more of: alleviation of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing or delaying spread of disease, preventing or delaying occurrence or recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, and remission (whether partial or total).
  • treatment is a reduction of pathological consequence of an angiogenesis-associated disease.
  • the methods of the invention contemplate any one or more of these aspects of treatment.
  • the methods are useful for treatment of non-tumorous angiogenesis-associated diseases in the eye tissue, such as in the cornea, retina, macula, and choroids.
  • the methods are generally useful for preventing blindness, loss of vision (such as loss of visual acuity or visual field), and/or other consequences resulting from a variety of eye diseases.
  • a method for treating macular degeneration including age-related macular degeneration (AMD). AMD is clinically characterized by progressive loss of central vision which occurs as a result of damage to the photoreceptor cells in an area of the retina called the macula.
  • AMD age-related macular degeneration
  • AMD has been broadly classified into two clinical states: a wet form and a dry form, with the dry form making up to 80-90% of total cases.
  • the dry form is characterized clinically by the presence of macular drusen, which are localized deposits between the retinal pigment epithelium (RPE) and the Brunch's membrane, and by geographic atrophy characterized by RPE cell death with overlying photoreceptor atrophy.
  • RPE retinal pigment epithelium
  • Wet AMD which accounts for approximately 90% of serious vision loss, is associated with neovascularization in the area of the macular and leakage of these new vessels. The accumulation of blood and fluid can cause retina detachment followed by rapid photoreceptor degeneration and loss of vision. It is generally accepted that the wet form of AMD is preceded by and arises from the dry form.
  • the methods provided herein are particularly useful in the treatment or inhibition of the wet form of macular degeneration.
  • Inhibition of angiogenesis in the eye tissue also prevents or delays the transition from the dry form of macular degeneration to the wet form of macular degeneration.
  • the invention thus also provides methods for the treatment of the dry form of macular degeneration.
  • the invention also encompasses methods of treating or preventing one or more aspects or symptoms of macular degeneration, including, but not limited to, loss of photoreceptor cells, loss of vision (including for example visual acuity and visual field), and retina detachment.
  • non-tumorous angiogenesis-associated eye diseases that can be treated by methods described herein include, but are not limited to, neovascularization of the retina, neovascularization of the cornea (such as that caused by trachoma, infections, inflammation, transplantations or trauma), diabetic retinopathy, diabetic retinal edema, diabetic macula edema, ischemic retinopathy, hypertensive retinopathy, occlusive retinopathy, retinopathy of prematurity, neovascularization subsequent to trauma, neovascularization subsequent to infection, neovascularization subsequent to transplantation, neovascularization subsequent to retinal detachment or retinal degeneration, neovascular glaucoma, anterior chamber and/or anterior chamber angle neovascularization, choroidal neovascularization (CNV), subretinal neovascularization, retrolental fibroplasias, ocular histoplasmos
  • CNV
  • cardiovascular diseases such as atherosclerosis, restenosis, atheroma, and haemangioma.
  • Atherosclerosis is a form of chronic vascular injury in which some of the normal vascular smooth cells (VSMC) in the artery wall change their nature and develop dense networks of capillaries in atherosclerotic plaques. These fragile microvessels can cause hemorrhages, leading to blood clotting, with a subsequent decreased blood flow to the heart muscle and heart attack.
  • Restenosis typically occurs after coronary artery bypass surgery, endaterectomy, and heart transplantation, and particularly after heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting. It involves extensive growth of microvessels.
  • the methods provided herein are useful for treating these cardiovascular diseases.
  • the methods are useful for treatment of rheumatoid arthritis, where blood vessels in the joints undergo angiogenesis to form an extensively vascularized tissue that invades and destroys the cartilage.
  • angiogenesis By inhibiting angiogenesis in the arthritic tissue, the methods provided herein are useful for treating rheumatoid arthritis. Methods of treating hemophiliac joints are also provided.
  • the methods are useful for treating angiogenesis- associated skin diseases, including, but are not limited to, psoriasis, scleroderma, neovascularization as a consequence of infection (e.g., cat scratch disease, bacterial ulceration, etc.), and other skin disorders.
  • the methods are useful for treating psoriasis.
  • Psoriasis is a chronic skin disease occurring in approximately 3% of the population worldwide. Histologic studies, including electron microscopy, have established that alterations in the blood vessel formation of the skin are a prominent feature of psoriasis. Inhibition of angiogenesis in the skin tissue is thus useful for treating psoriasis.
  • angio genesis-associated diseases that can be treated by methods of the present invention include, but are not limited to, Osier- Webber Syndrome, hereditary hemorrhagic telangiectasia, plaque neovascularization, telangiectasia, angiofibroma, angioma, wound granularization, endometriosis, and the like.
  • the invention is useful for treatment of nasal polyps, especially in cystic fibrosis patients.
  • angiogenesis-associated diseases can also be used to modulate or prevent the occurrence of normal physiological conditions associated with angiogenesis.
  • the inventive method can be used to attenuate neovascularization associated with ovulation, implantation of an embryo, placenta formation, etc, and are thus useful for birth control purposes.
  • a method of treating a non-tumorous angiogenesis- associated disease in an individual comprising administering to the individual a composition (such as a composition comprising a carrier protein) comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating the non-tumorous angiogenesis-associated disease.
  • a composition such as a composition comprising a carrier protein
  • thiocolchicine dimer comprising a colchicine or thiocolchicine dimer
  • angiogenesis-associated eye disease including for example macular degeneration, diabetic retinopathy, or neovascular glaucoma
  • a composition such as a composition comprising a carrier protein
  • a colchicine or thiocolchicine dimer comprising a colchicine or thiocolchicine dimer
  • a method of treating a cardiovascular disease comprising administering to the individual a composition (such as a composition comprising a carrier protein) a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating the cardiovascular disease.
  • a method of treating an angiogenesis- associated skin disease comprising administering to the individual a composition (such as a composition comprising a carrier protein) comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating the skin disease.
  • a method of treating arthritis comprising administering to the individual a composition (such as a composition comprising a carrier protein) comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating arthritis.
  • a composition such as a composition comprising a carrier protein
  • thiocolchicine dimer comprising a colchicine or thiocolchicine dimer
  • the colchicine or thiocolchine dimer composition is administered at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily.
  • the interval between each administration is less than about a week, such as less than about any of 6, 5, 4, 3, 2, or 1 day(s).
  • the interval between each administration is constant.
  • the administration can be carried out daily, every two days, every three days, every four days, every five days, or weekly.
  • the administration can be carried out twice daily, three times daily, or more frequent.
  • the administration of the composition can be extended (with or without breaks) over an extended period of time, such as from about a month up to about three years.
  • the dosing regime can be extended (with or without breaks) over a period of any of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, and 36 months.
  • the interval between each administration is no more than about a week.
  • Methods of treating tumor-related diseases by inhibiting angiogenesis are also useful for inhibition of angiogenesis in tumor tissues and for treating tumor-related diseases such as cancers and benign tumors.
  • Inhibiting angiogenesis prevents sufficient nutrients and oxygen from being supplied to the tumor to support growth beyond a given size. Because angiogenesis is involved in both primary tumor growth and metastasis, the methods provided herein are capable of inhibiting neoplastic growth of tumor at the primary site as well as preventing metastasis of tumors at the secondary sites.
  • the colchicine or thiocolchicine dimer inhibits new blood vessel formation.
  • the colchicine or thiocolchicine dimer composition disrupts established tumor vasculature.
  • the compositions may be effective in the selective occlusion, dissolution, or otherwise affect, whether reversible or irreversible, partial or complete, of tumor vasculature (sometimes proliferating tumor vasculature).
  • the invention provides methods of treating tumor-related disease by administering an effective amount of a composition comprising a colchicine or thiocolchicine dimer, wherein the amount of the composition is insufficient to induce significant cytotoxicity (also referred to as a "noncytotoxic dose").
  • cytotoxicity also referred to as a "noncytotoxic dose”
  • Traditional chemotherapy with a cytotoxic agent is typically carried out at a dose that is either the same or close to the maximum tolerated dose of the agent in order to maximize the cytotoxic effect of the agent.
  • This high-dose schedule requires an extended treatment-free period to allow recovery of normal host cells. In the meantime, tumor cells may also resume growth during the treatment free period. This could increase the risk of the developing drug resistant tumor cells.
  • a noncytotoxic dose of a colchicine or thiocolchicine dimer allows cancer treatment without significant breaks in the treatment cycle, thus reduces the risk of developing drug resistance.
  • a method of treating cancer in an individual comprising administering to the individual a composition comprising a colchicine or thiocolchicine dimer, wherein the composition is in an amount that is effective in treating cancer, and wherein the amount of colchicine or thiocolchicine dimer in the composition per administration is less than about any of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% of the corresponding MTD for the same (or similar) colchicine or thiocolchicine dimer in a same (or similar) formulation following a same or similar dosing schedule or a traditional dosing schedule.
  • the amount of colchicine or thiocolchicine dimer in the composition per administration is between about 1% to about 15% of the corresponding MTD, including for example any of about 1% to about 12%, about 1% to about 10%, about 1% to about 8%, about 1% to about 5%, about i% to about 3%, of the corresponding MTD.
  • the MTD for a colchicine or thiocolchicine dimer is known or can be easily determined by a person skilled in the art. For example, the MTD for Nab-5404 following a weekly schedule is about 90-100 mg/m 2 body surface.
  • the colchicine or thiocolcliine dimer composition is administered at least about any of once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily.
  • the interval between each administration is less than about a week, such as less than about any of 6, 5, 4, 3, 2, or 1 day(s).
  • the interval between each administration is constant.
  • the administration can be carried out daily, every two days, every three days, every four days, every five days, or weekly.
  • the administration can be carried out twice daily, three times daily, or more frequent.
  • the administration of the composition can be extended (with or without breaks) over an extended period of time, such as from about a month up to about three years.
  • the dosing regime can be extended (with or without breaks) over a period of any of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, and 36 months.
  • the interval between each administration is no more than about a week.
  • cancers include, but are not limited to, squamous cell cancer, lung cancer (including small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung), cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, heptoma, breast cancer, colon cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, head and neck cancer, B-cell lymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease
  • NHL
  • the cancer is lung cancer, including, for example, non-small cell lung cancer (NSCLC, such as advanced NSCLC), small cell lung cancer (SCLC, such as advanced SCLC), and advanced solid tumor malignancy in the lung.
  • NSCLC non-small cell lung cancer
  • SCLC small cell lung cancer
  • the cancer is ovarian cancer, head and neck cancer, gastric malignancies, melanoma (including metastatic melanoma), colorectal cancer, pancreatic cancer, and solid tumors (such as advanced solid tumors).
  • the cancer is any of (and in some embodiments selected from the group consisting of) breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma, Kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, melanoma, ovarian cancer, mesothelioma, gliomas, glioblastomas, neuroblastomas, and multiple myeloma.
  • the cancer is a solid tumor.
  • Adjuvant setting refers to a clinical setting in which an individual has had a history of cancer, and generally (but not necessarily) been responsive to therapy, which includes, but is not limited to, surgery (such as surgical resection), radiotherapy, and chemotherapy. However, because of their history of the cancer, these individuals are considered at risk of development of the disease. Treatment or administration in the "adjuvant setting” refers to a subsequent mode of treatment. The degree of risk (i.e., when an individual in the adjuvant setting is considered as "high risk” or "low risk”) depends upon several factors, most usually the extent of disease when first treated.
  • the methods provided herein may also be practiced in a neoadjuvant setting, i.e., the method may be carried out before the primary/definitive therapy.
  • the individual has previously been treated.
  • the individual has not previously been treated.
  • the treatment is a first line therapy.
  • the methods described herein may be carried out in conjunction with other methods of cancer treatment (for example, in a combination therapy setting).
  • the method comprises a first therapy comprising administering a composition comprising a colchicine or thiocolchicine dimer, and a second therapy.
  • the second therapy is chemotherapy.
  • the second therapy is radiation therapy.
  • the second therapy is surgery.
  • the first and second therapy can be carrier out either simultaneously or sequentially (i.e., the first therapy is carrier out before or after the second therapy).
  • the method comprises co-administering (including simultaneously or sequentially) a composition comprising a colchicine or thiocolchicine dimer with a second chemotherapeutic agent to an individual, wherein the composition is effective in inhibiting angiogenesis in the individual, and wherein the composition is in an amount that is insufficient to induce cytotoxicity in the individual.
  • the second chemotherapeutic agent is a cytotoxic agent.
  • composition comprising colchicine or thiocolchicine dimers
  • compositions comprising a colchicine or thiocolchicine dimer.
  • Colchicine or thiocolchicine dimer used herein refers to a compound containing two (same or different) subunits of colchicine, thiocolchicine, or derivatives thereof.
  • Derivatives of colchicine or thiocolchicine include, but are not limited to, compounds that are structurally similar to colchicine or thiocolchine or are in the same general chemical class as colchicine and thiocolchicine.
  • the derivative or analog of colchicine or thiocolchine retains similar biological, pharmacological, chemical and/or physical properties (including, for example, functionality) of colchicine or thiocolchicine.
  • the colchicine or thiocolchicine dimer comprises at least one thiocolchicine subunit.
  • the colchicine or thiocolchicine dimer comprises two thiocolchicine subunits (hereinafter referred to as "thiocolchicine dimer").
  • the colchicine or thiocolchicine dimer comprises two colchicine subunits (herein after referred to as "colchicine dimer").
  • the colchicine or thiocolchicine dimer is a compound of formula (I):
  • each subunit is either a methoxy or a methylthio group
  • R 2 is methoxy, hydroxyl, or methylenedioxy when taken together with R 3
  • R 3 is methoxy, hydroxy 1, or methylenedioxy when taken together with R 2
  • X is a linking group
  • a wide variety of cross-linking groups can be used to introduce the linking group X.
  • the colchine or thiocolchicine monomer components of the dimer have a single reactive amino group; should any other reactive (nucleophilic) groups be present on the intermediates, they can be readily protected using groups well-known in the art.
  • protecting groups see, for example, Greene, T. W., and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, Wiley: New York, 1999, the contents of which are hereby incorporated herein by reference in their entirety.
  • cross-linking groups reactive with the amine functionality can be employed.
  • the linking group X comprises at least one carbon atom.
  • the commercially available (Sigma-Aldrich) reagent malonyl chloride, Cl-C(O)-CH 2 -C(O)-Cl can be used to form a colchicine dimer where the X group is -CH 2 -.
  • other diacyl chlorides of varying lengths can be used to form X groups of desired length.
  • the colchicine or thiocolchicine dimer is a compound of the formula (II):
  • B 1 is a methoxy or a methylthio group
  • B 2 is a methoxy or a methylthio group
  • n is an integer from 0 to 8
  • Y is a CH 2 group or, when n is 1, can also be a group of formula NH.
  • n is any of (and in some embodiments selected from the group consisting of) 0, 1, 2, 3, 4, 5, 6, 7, or 8. In some embodiments, n is 1. In some embodiments, n is 1 and Y is NH. In some embodiments, n is 2.
  • both B 1 and B 2 are methoxy groups. In some embodiments, both B 1 and B 2 are methylthio groups. In some embodiments, B 1 is methoxy group and B 2 is methylthio group. In some embodiments, B 1 is methylthio group and B 2 is methoxy group.
  • the colchicine or thiocolchicine dimer is any of (and in some embodiments selected from the group consisting of): IDN5404, IDN5676, IDN5800, and IDN5801.
  • the compound is thiocolchicine dimer IDN5404.
  • IDN5404 is a compound of formula (III):
  • the compound is thiocolchicine dimer IDN5676.
  • IDN5676 is a compound of formula (IV):
  • the colchicine or thiocolchicine dimer compositions described herein further comprise a biocompatible polymer such as a carrier protein.
  • a biocompatible polymer such as a carrier protein.
  • Biocompatible polymer includes naturally-occurring or synthetic biocompatible materials such as proteins, polynucleotides, polysaccharides (e.g., starch, cellulose, dextrans, alginates, chitosan, pectin, hyaluronic acid, and the like), and lipids.
  • Suitable biocompatible polymers include, for example, naturally occurring or synthetic proteins such as albumin, insulin, hemoglobin, lysozyme, immunoglobulins, ⁇ -2- macroglobulin, fibronectin, vitronectin, fibrinogen, casein and the like, as well as combinations of any two or more thereof.
  • Synthetic polymers include, for example, polyalkylene glycols (e.g., linear or branched chain), polyvinyl alcohol, polyacrylates, polyhydroxyethyl methacrylate, polyacrylic acid, polyethyloxazoline, polyacrylamides, polyisopropyl acrylamides, polyvinylpyrrolidone, polylactide/glycolide and the like, and combinations thereof.
  • proteins refers to polypeptides or polymers of amino acids of any length (including full length or fragments), which may be linear or branched, comprise modified amino acids, and/or be interrupted by non-amino acids.
  • the term also encompasses an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • the proteins described herein may be naturally occurring, i.e., obtained or derived from a natural source (such as blood), or synthesized (such as chemically synthesized or by synthesized by recombinant DNA techniques).
  • suitable carrier proteins include proteins normally found in blood or plasma, which include, but are not limited to, albumin, immunoglobulin including IgA, lipoproteins, apolipoprotein B, alpha-acid glycoprotein, beta-2-macroglobulin, thyroglobulin, transferin, fibronectin, factor VII, factor VIII, factor IX, factor X, and the like, hi some embodiments, the carrier protein is a non-blood protein, such as casein, ⁇ - lactalbumin, and ⁇ -lactoglobulin.
  • the carrier proteins may either be natural in origin or synthetically prepared.
  • the carrier protein is an albumin, such as human serum albumin.
  • HSA Human serum albumin
  • HSA solution Intravenous use of HSA solution has been indicated for the prevention and treatment of hypovolumic shock (see, e.g., Tullis, JAMA, 237, 355-360, 460-463, (1977)) and Houser et al, Surgery, Gynecology and Obstetrics, 150, 811-816 (1980)) and in conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia (see, e.g., Finlayson, Seminars in Thrombosis and Hemostasis, 6, 85-120, (1980)).
  • Other albumins are contemplated, such as bovine serum albumin. Use of such non-human albumins could be appropriate, for example, in the context of use of these compositions in non-human mammals, such as the veterinary animals (including domestic pets and agricultural animals).
  • HSA Human serum albumin
  • hydrophobic binding sites a total of eight for fatty acids, an endogenous ligand of HSA
  • binds a diverse set of drugs, especially neutral and negatively charged hydrophobic compounds Goodman et al., The Pharmacological Basis of Therapeutics, 9 th ed, McGraw-Hill New York (1996).
  • Two high affinity binding sites have been proposed in subdomains HA and IIIA of HSA, which are highly elongated hydrophobic pockets with charged lysine and arginine residues near the surface which function as attachment points for polar ligand features (see, e.g., Fehske et al., Biochem.
  • the carrier protein (such as albumin) in the composition generally serves as a carrier for the colchicine or thiocolchicine dimer, i.e., the carrier protein in the composition makes the colchicine or thiocolchicine dimer more readily suspendable in an aqueous medium or helps maintain the suspension as compared to compositions not comprising a carrier protein. This can avoid the use of toxic solvents for solubilizing the colchicine or thiocolchicine dimer, and thereby can reduce one or more side effects caused by those toxic solvent.
  • the composition is substantially free of surfactants, i.e., the amount of surfactant in the composition is not sufficient to cause one or more side effect(s) in an individual when the composition is administered to the individual.
  • the composition is fee of surfactants.
  • the carrier protein is associated with the colchicine or thiocolchicine dimer, i.e., the composition comprises carrier protein-associated colchicine or thiocolchicine dimer.
  • "Association" or “associated” is used herein in a general sense and refers to the carrier protein affecting a behavior and/or property of the colchicine or thiocolchicine dimer in an aqueous composition.
  • the carrier protein and the colchicine or thiocolchicine dimer are considered as being “associated” if the carrier protein makes the colchicine or thiocolchicine dimer more readily suspendable in an aqueous medium as compared to a composition without the carrier protein.
  • the carrier protein and the colchicine or thiocolchicine dimer is associated if the carrier protein stabilizes the colchicine or thiocolchicine dimer in an aqueous suspension.
  • the carrier protein and the colchicine or thiocolchicine dimer can be present in a particle or a nanoparticle, which are further described herein.
  • a colchicine or thiocolchicine dimer is "stabilized" in an aqueous suspension if it remains suspended in an aqueous medium (such as without visible precipitation or sedimentation) for an extended period of time, such as for at least about any of 0.1, 0.2, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, 48, 60, or 72 hours.
  • the suspension is generally, but not necessarily, suitable for administration to an individual (such as human). Stability of the suspension is generally (but not necessarily) evaluated at a storage temperature (such as room temperature (such as 20-25 0 C) or refrigerated conditions (such as 4 0 C)).
  • a suspension is stable at a storage temperature if it exhibits no flocculation or particle agglomeration visible to the naked eye or when viewed under the optical microscope at 1000 times, at about fifteen minutes after preparation of the suspension. Stability can also be evaluated under accelerated testing conditions, such as at a temperature that is higher than about 40 0 C.
  • the carrier protein and the colchicine or thiocolchicine dimer in the composition can be associated in various manners.
  • the carrier protein is in admixture with the colchicine or thiocolchicine dimer.
  • the carrier protein encapsulates or entraps the colchicine or thiocolchicine dimer.
  • the carrier protein is bound (such as non-covalently bound) to the colchicine or thiocolchicine dimer.
  • the composition may exhibit one or more of the above aspects.
  • the composition comprises particles (such as microparticles or nanoparticles) comprising (in various embodiments consisting essentially of) a colchicine or tbiocolchicine dimer and a carrier protein (such as albumin).
  • the colchicine or tbiocolchicine dimer is coated with the carrier protein (such as albumin).
  • the composition comprises nanoparticles (i.e., particles with an average or mean diameter of no greater than about 1000 nanometers (nm)), such as no greater than about any of 900, 800, 700, 600, 500, 400, 300, 200, and 100 nm.
  • the average or mean diameters of the nanoparticles in the composition is no greater than about 200 nm. In some embodiments, the average or mean diameter of the nanoparticles in the composition is between about 20 to about 400 nm. In some embodiments, the average or mean diameter of the nanoparticles is between about 40 to about 200 nm. In some embodiments, the nanoparticles are sterile-filterable. [0103]
  • the particles (such as microparticles or nanoparticles) described herein may be present in a dry formulation (such as lyophilized composition) or suspended in a biocompatible medium.
  • Suitable biocompatible media include, but are not limited to, water, buffered aqueous media, saline, buffered saline, optionally buffered solutions of amino acids, optionally buffered solutions of proteins, optionally buffered solutions of sugars, optionally buffered solutions of vitamins, optionally buffered solutions of synthetic polymers, lipid-containing emulsions, and the like.
  • the amount of carrier protein in the composition described herein will vary depending on the pharmaceutical agent and other components in the composition.
  • the composition comprises a carrier protein in an amount that is sufficient to stabilize the colchicine or thiocolchicine dimer in an aqueous suspension, for example, in the form of a stable colloidal suspension (such as a stable suspension of microparticles or nanoparticles).
  • the carrier protein is in an amount that reduces the sedimentation rate of the colchicine or thiocolchicine dimer in an aqueous medium.
  • the amount of the carrier protein also depends on the size and density of particles of the colchicine or thiocolchicine dimer.
  • the carrier protein is present in an amount that is sufficient to stabilize the colchicine or thiocolchicine dimer in an aqueous suspension at a certain concentration.
  • concentration of the colchicine or thiocolchicine dimer in the composition is about 0.01 to about 100 mg/ml, including for example any of about 0.01 to about 50 mg/ml, about 0.1 to about 50 mg/ml, about 1 to about 10 mg/ml, about 2 mg/ml to about 8 mg/ml, about 4 to about 6 mg/ml, about 5 mg /ml.
  • the concentration of the colchicine or thiocolchicine dimer is at least about any of 0.01 mg/ml, 0.03 mg/ml, 0.05 mg/ml, 0.08 mg/ml, 0.1 mg/ml, 0.3 mg/ml, 0.5 mg/ml, 0.8 mg/ml, 1 mg/ml, 1.3 mg/ml, 1.5 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml, 25 mg/ml, 30 mg/ml, 40 mg/ml, and 50 mg/ml.
  • the carrier protein is present in an amount that avoids use of surfactants, so that the composition is free or substantially free of surfactant.
  • the composition, in liquid form comprises from about 0.1% to about 50% (w/v) (e.g. about 0.5% (w/v), about 5% (w/v), about 10% (w/v), about 15% (w/v), about 20% (w/v), about 30% (w/v), about 40% (w/v), or about 50% (w/v)) of carrier protein. In some embodiments, the composition, in liquid form, comprises about 0.5% to about 5% (w/v) of carrier protein.
  • the weight ratio of carrier protein, e.g., albumin, to the colchicine or thiocolchicine dimer is such that a sufficient amount of colchicine or thiocolchicine dimer binds to, or is transported by, the cell.
  • the weight ratio of carrier protein, e.g., albumin, to colchicine or thiocolchicine dimer is about 0.01:1 to about 100:1, about 0.02:1 to about 50:1, about 0.05:1 to about 20:1, about 0.1:1 to about 20:1, about 1:1 to about 18:1, about 2:1 to about 15:1, about 3:1 to about 12:1, about 4:1 to about 10:1, about 5:1 to about 9:1, or about 9:1.
  • the carrier protein (such as albumin) to colchicine or thiocolchicine dimer weight ratio is about any of 18:1 or less, 15:1 or less, 14:1 or less, 13:1 or less, 12:1 or less, 11:1 or less, 10:1 or less, 9:1 or less, 8:1 or less, 7:1 or less, 6:1 or less, 5:1 or less, 4:1 or less, and 3:1 or less.
  • the composition comprises particles (such as microparticles or nanoparticles) comprising (in various embodiments consisting essentially of) thiocolchicine dimer (such as IDN5404 or IDN5676) and albumin.
  • the particles may have an average or mean diameter of no greater than about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 micron.
  • the particle is a nanoparticle, i.e., a particle that is less than about 1000 nanometers (nm).
  • the nanoparticle may be no greater than about any of 900, 800, 700, 600, 500, 400, 300, 200, and 100 nm.
  • the average or mean diameters of the nanoparticles is no greater than about 200 nm. In some embodiments, the average or mean diameter of the nanoparticles is between about 20 to about 400 nm. In some embodiments, the average or mean diameter of the nanoparticles is between about 40 to about 200 nm. In some embodiments, the particles are sterile-filterable.
  • the thiocolchicine dimer (such as IDN5404 or
  • the weight ratio of albumin to thiocolchicine dimer (such as IDN5404 or IDN5676) (w/w) is any of about 0.01:1 to about 100: 1 , about 0.02: 1 to about 50:1, about 0.05 : 1 to about 20: 1 , about 0.1 : 1 to about 20: 1 , about 1:1 to about 18:1, about 2:1 to about 15:1, about 3:1 to about 12:1, about 4:1 to about 10:1, about 5:1 to about 9:1, and about 9:1.
  • the albumin to thiocolchicine dimer weight ratio is less than about any of 18:1 or less, 15:1 or less, 14:1 or less, 13:1 or less, 12:1 or less, 11:1 or less, 10:1 or less, 9:1 or less, 8:1 or less, 7:1 or less, 6:1 or less, 5:1 or less, 4:1 or less, and 3:1 or less.
  • the particles (such as microparticles or nanoparticles) comprising thiocolchicine dimer (such as IDN5404 or IDN5676) and albumin are suspended in an aqueous medium (such as an aqueous medium containing the albumin).
  • the composition can be a colloidal suspension of thiocolchicine dimer (such as IDN5404 or IDN5676)-containing particles (such as microparticles or nanoparticles).
  • the composition is a dry composition (such as lyophilized composition) that can be reconstituted to an aqueous suspension of thiocolchicine dimer (such as IDN5404 or IDN5676)-containing particles.
  • the concentration of thiocolchicine dimer (such as IDN5404 or IDN5676) in the composition is between about 0.1 to about 100 mg/ml, including for example any of about 0.1 to about 50 mg/ml, about 0.1 to about 20 mg/ml, about 1 to about 10 mg/ml, about 2 mg/ml to about 8 mg/ml, about 4 to about 6 mg/ml, and about 5 mg /ml.
  • the concentration of IDN5404 or IDN5676 is at least about any of 1.3 mg/ml, 1.5 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml, 25 mg/ml, 30 mg/ml, 40 mg/ml, and 50 mg/ml.
  • the composition comprises a nanoparticle formulation of IDN5404 or IDN5676 (hereinafter referred to as Nab-5404 oxNab-5676).
  • jV ⁇ &-IDN5404 and Nab-5676 are nanoparticle formulation of IDN5404 and IDN5676, respectively, stabilized by human serum albumin. These nanoparticle formulations can be generated by methods described in U.S. Patent No. 5,916,596 and U.S. Pat. App. Pub. No. 2005/0004002.
  • JV ⁇ -5404 orNab-5676
  • JV ⁇ -5404 forms a stable colloidal suspension of thiocolchicine dimer.
  • the size (i.e., average or mean diameter) of the particles in the colloidal suspension may range from 20 nm to 8 microns with a preferred range of about 20-400 nm.
  • Nab-5404 (or Nab-5676) can be reconstituted in a wide range of concentrations ranging from dilute (0.1 mg/ml IDN5404 or IDN5676) to concentrated (20 mg/ml IDN5404 or IDN5676), including for example about 2 mg/ml to about 8 mg/ml, about 5 mg/ml.
  • the IDN5404 or IDN5676 concentration is about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 mg/ml.
  • compositions comprising a colchicine or thiocolchicine dimer.
  • the pharmaceutical composition may be suitable for a variety of modes of administration described herein, including for example systemic or local administration.
  • the pharmaceutical composition can be in the form of eye drops, injectable solutions, or in a form suitable for inhalation (either through mouth or nose), or oral administration.
  • the pharmaceutical compositions described herein can be packaged in single unit dosages or in multidosage forms.
  • the composition is suitable for administration to a human.
  • the composition is suitable for administration to a mammal such as, in the veterinary context, domestic pets and agricultural animals.
  • suitable formulations of the composition see, e.g., U.S. Pat. Nos. 5,916,596 and 6,096,331).
  • the pharmaceutical composition comprises a colchicine or thiocolchicine dimer, a carrier protein, and a pharmaceutically acceptable carrier suitable for intraocular injection.
  • the pharmaceutical composition comprises a colchicine or thiocolchicine dimer, a carrier protein, and a pharmaceutically acceptable carrier suitable for topical application to the eye.
  • the pharmaceutical composition comprises a colchicine or thiocolchicine dimer, a carrier protein, and a pharmaceutically acceptable carrier suitable for intraarterial injection.
  • the pharmaceutical compositions are generally formulated as sterile and substantially isotonic compositions.
  • the pharmaceutical composition can be in the form of liquid solutions, for example, in physiologically compatible buffers such as Hank's solution or Ringer's solution.
  • the pharmaceutical composition can also be in a solid form and redissolved or resuspended immediately prior to use. Lyophilized compositions are also included.
  • the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate).
  • binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato star
  • Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., ationd oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
  • emulsifying agents e.g., lecithin or acacia
  • non-aqueous vehicles e.g., ationd oil, oily esters,
  • compositions comprising a colchicine or thiocolchicine dimer, a carrier protein, and a pharmaceutically acceptable carrier suitable for administration to the eye.
  • pharmaceutical carriers can be sterile liquids, such as water and oil, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and the like. Saline solutions and aqueous dextrose, polyethylene glycol (PEG) and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, sodium stearate, glycerol monostearate, glycerol, propylene, water, and the like.
  • the pharmaceutical composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the components of the composition may be encased in polymers or fibrin glues to provide controlled release of the molecule.
  • These compositions can take the form of solutions, suspensions, emulsions, ointment, gel, or other solid or semisolid compositions, and the like.
  • the compositions typically have a pH in the range of 4.5 to 8.0.
  • compositions must also be formulated to have osmotic values that are compatible with the aqueous humor of the eye and ophthalmic tissues.
  • osmotic values will generally be in the range of from about 200 to about 400 milliosmoles per kilogram of water (“mOsm/kg”), but will preferably be about 300 mOsm/kg.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for injection intravenously, introperitoneally, or intravitreously.
  • compositions for injection are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • compositions are to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • the compositions may further comprise additional ingredients, for example preservatives, buffers, tonicity agents, antioxidants and stabilizers, nonionic wetting or clarifying agents, viscosity-increasing agents, and the like.
  • Suitable preservatives for use in a solution include polyquaternium-1, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, benzethonium chloride, and the like.
  • such preservatives are employed at a level of from 0.001% to 1.0% by weight.
  • Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient to maintain the pH at between about pH 6 and pH 8, and preferably, between about pH 7 and pH 7.5.
  • Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the ophthalmic solution is in the range 0.9 plus or minus 0.2%.
  • Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium thiosulfite, thiourea and the like.
  • Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol.
  • Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxmethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose and the like.
  • viscosity enhancing agents to provide topical compositions with viscosities greater than the viscosity of simple aqueous solutions may be desirable to increase ocular absorption of the active compounds by the target tissues or increase the retention time in the eye.
  • viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents know to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight.
  • compositions described herein can also include other agents, excipients, or stabilizers to improve properties of the composition.
  • negatively charged components include, but are not limited to bile salts of bile acids consisting of glycocholic acid, cholic acid, chenodeoxycholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, litocholic acid, ursodeoxycholic acid, dehydrocholic acid and others; phospholipids including lecithin (egg yolk) based phospholipids which include the following phosphatidylcholines : palmitoyloleoylphosphatidylcholine, palmitoyllinoleoylphosphatidylcholine , stearoyllinoleoylphosphatidylcholine stearoyloleoylphosphatid
  • phospholipids including L- ⁇ - dimyristoylphosphatidylcholine (DMPC), dioleoylphosphatidylcholine (DOPC), distearoylphosphatidylcholine (DSPC), hydrogenated soy phosphatidylcholine (HSPC), and other related compounds.
  • Negatively charged surfactants or emulsifiers are also suitable as additives, e.g., sodium cholesteryl sulfate and the like.
  • unit dosage forms of colchicine or thiocolchicine dimer compositions for example, a unit dosage containing from about 0.1 mg to about 50 mg, including for example about 0.2 mg to about 50 mg, about 0.5 mg to about 30 mg, about 1 mg to about 20 mg, or about 15 mg of the colchicine or thiocolchicine dimer.
  • unit dosage form refers to a physically discrete unit suitable as unitary dosages for an individual, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient.
  • These unit dosage forms can be stored in a suitable packaging in single or multiple unit dosages and may also be further sterilized and sealed.
  • a unit dosage form of colchicine or thiocolchicine dimer and a carrier protein that is suitable for intraocular injection. In some embodiments, there is provided a unit dosage form of colchicine or thiocolchicine dimer and a carrier protein that is suitable for topical application to the eye. In some embodiments, there is provided a unit dosage form of colchicine or thiocolchicine dimer and a carrier protein that is suitable for intraarterial injection.
  • compositions described herein are known in the art, and include, for example, vials (such as sealed vials), vessels, ampules, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. These articles of manufacture may further be sterilized and/or sealed.
  • kits comprising compositions (or unit dosages forms and/or articles of manufacture) described herein and may further comprise instruction(s) on methods of using the composition, such as uses described herein.
  • the kits described herein may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.
  • the kit comprises a colchicine or thiocolchicine dimer, a carrier protein, a pharmaceutically acceptable carrier suitable for intraocular injection, and one or more of: a buffer, a diluent, a filter, a needle, a syringe, and a package insert with instructions for performing intraocular injection.
  • the pharmaceutical composition comprises a colchicine or thiocolchicine dimer, a carrier protein, a pharmaceutically acceptable carrier suitable for intraarterial injection, and one or more of: a buffer, a diluent, a filter, a needle, a syringe, and a package insert with instructions for performing intraarterial injection.
  • Example 1 In vitro Cytotoxity Activity of Nab-5404 and Nab-5676 [0129] The cytotoxic activities of Nab-5404 and Nab-5676 were evaluated in vitro using MX-I breast carcinoma, HepG2 hepatoma, HT-29 colon carcinoma cell lines and normal primary rat hepatocytes. Cells were exposed to Nab-5404 and Nab-5676 for 72 hours at 37°C across a range of increasing concentrations. Viability was analyzed using a Cell Titer Blue cell viability assay (Promega, Madison, WI). IC50s were calculated with a one-phase exponential decay equation using Prism software (GraphPad, San Diego, CA).
  • Nab-5404 demonstrated cytotoxic activity against HepG2 hepatoma cells and primary rat hepatocytes, with IC50s of 16 and 9 ⁇ g/ml respectively. Both Nab-5404 and Nab-5676 were moderately cytotoxic against MX-I cells, with IC50s of 43 and 54 ⁇ g/ml respectively. Activity of Nab-5404 and Nab-5676 against HT-29 cells was low with IC50s of 110 and 149 ⁇ g/ml, respectively. Nab-5676 showed little or no cytotoxic activity in HepG2 cells or primary rat hepatocytes. Results are summarized in Table 1.
  • Example 2 Anti-microtubule Activity of Nab-5404 and Nab-5676
  • the microtubule depolymerization activities of Nab-5404 and Nab-5676 were tested using the MX-I breast carcinoma cell line. MX-I cells were seeded on cover slips and treated with Nab-5404 or Nab-5676 for 2 hours at 37°C across a concentration range of 0.01 to 100 ⁇ g/ml. After incubation, the cells were fixed and stained for tubulin and actin. Tubulin was stained with monoclonal anti-tubulin antibody and actin was stained with fluorescein-labeled phalloidin.
  • microtubule network was visualized and analyzed using ImagePro Software (MediaCybernetics, Inc., Silver Spring MD). IC50s for Nab-5404 and Nab-5676 activity on microtubule destabilization were calculated using Prism software (GraphPad, San Diego, CA).
  • Both Nab-5404 and Nab-5676 exhibited potent microtubule depolymerization activity with calculated IC50s of 0.06 ⁇ g/ml and 0.12 ⁇ g/ml, respectively ( Figures IA and IB). Even at the lowest concentration tested, 0.6 ⁇ g/ml, the microtubule network was completely destroyed after a two-hour incubation with Nab-5404 or Nab-5676 ( Figures 2A-2C). In contrast, actin bundles were not affected by Nab-5404 or Nab-5676 at any drug concentration.
  • Example 3 Anti-angiogenic Activity of Nab-5404 and Nab-5676 [0133] To study the effect of Nab-5404 and Nab-5676 on angiogenesis, the compounds were evaluated in a microvessel formation assay using a TCS CellWorks AngioKit model (TCS CellWorks Ltd., Botolph Claydon, Buckingham UK).
  • TCS CellWorks AngioKit model uses human endothelial cells co-cultured with other human cells. The endothelial cells initially form small islands within the culture matrix, then begin to proliferate and then enter a migratory phase during which they move through the matrix to form threadlike tubule structures. These gradually join up to form a network of tubules which closely resemble a capillary bed (at day 9-11). The tubules stain positive for von Willebrand's factor, CD31 (PECAM-I) and ICAM-2.
  • PECAM-I von Willebrand's factor
  • a known vascular targeting agent combretastatin 4-phosphate (CA4P)
  • CA4P combretastatin 4-phosphate
  • the TCS CellWorks AngioKit model was used according to the manufacturer's instructions.
  • human endothelial cells were co-cultured with human fibroblast cells in a 24 well plate and exposed to Nab-5404, Nab-5676 or CA4P across a range of concentrations (0.01 to 100 ⁇ g/ml). After a 11 or 12 day incubation, tubules were visualized by fixing the cells and staining using a monoclonal antibody against CD31, a secondary antibody conjugate and a colored substrate. The length of the tubules was analyzed using ImagePro software and the IC50 of each compound was calculated using Prism software.
  • Both Nab-5404 and Nab-5676 inhibited tubule formation and disrupted established tubules demonstrating anti-angiogenic activity.
  • the cells were treated with the compositions on day 1 and stained on day 12 for analysis of inhibition of tubule formation.
  • the cells were treated on day 8 and stained on day 11, while in the third experiment, the cells were treated on day 11 and stained on day 12 which allowed for analysis of the disruption of established tubules.
  • Both Nab-5404 and Nab-5676 were capable of inhibiting the formation of new microvessels ( Figures 3 and 4).
  • both Nab-5404 and Nab- 5676 were capable of inhibiting tubule formation and/or disrupting established tubules (Figure 5).
  • iV ⁇ -5404 was more potent than Nab-5676 in disrupting established tubules ( Figures 6, 7, and 9).
  • the IC50 of Nab-5404 was calculated to be 0.002 ⁇ g/ml, ten times more potent than Nab-5676 with an IC50 of 0.02 ⁇ g/ml.
  • the first cycle consisted of administration of Nab-5404 or Nab-5676 every 3 days for 4 doses for days 0-14 followed by the second cycle which consisted of administration of Nab-5404 or Nab-5676 every 3 days for 4 doses for days 15-30.
  • Irinotecan was administered by intravenous injection at a dose of 60 mg/kg every 3 days for 4 doses.
  • the individual groups are shown in Table 2, wherein 1 st cycle refers to days 0- 14 and 2 nd cycle refers to days 15-30. [0138] Table 2
  • Nab-5676 inhibited tumor growth significantly with p values of 0.02, 0.007, 0.001 for 3.4, 2.5, and 1.7 mg/kg of Nab-5404 and p values of 0.04, 0.003 and 0.0004 for 3.4, 2.5, and 1.7 mg/kg Nab-5676.
  • the anti-tumor activities of ⁇ f ⁇ -5404 and Nab-5676 at low doses suggest that these compounds have anti-angiogenic activities.
  • Combretastatin 4-phosphate (CA4P) was also administered to HT-29 tumor- bearing mice in a separate experiment.
  • CA4P was found to be inactive in this tumor model with no difference from the control vehicle ( Figure 12).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP06802881A 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases Withdrawn EP2056812A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/034365 WO2008027055A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Publications (1)

Publication Number Publication Date
EP2056812A1 true EP2056812A1 (en) 2009-05-13

Family

ID=37763804

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06802881A Withdrawn EP2056812A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Country Status (9)

Country Link
EP (1) EP2056812A1 (pt)
JP (1) JP2010502603A (pt)
CN (1) CN101568332A (pt)
AU (1) AU2006347740A1 (pt)
BR (1) BRPI0622006A2 (pt)
CA (1) CA2662140A1 (pt)
IL (1) IL197276A0 (pt)
MX (1) MX2009002054A (pt)
WO (1) WO2008027055A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008109163A1 (en) 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
EP2515930A4 (en) * 2009-12-21 2013-04-10 Tty Biopharm Co Ltd METHODS AND COMPOSITIONS BASED ON REDUCED MET PHOSPHORYLATION BY CHEMOTAXIN 2 DERIVED FROM LEUKOCYTE CELLS IN TUMOR CELLS
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
US20140228299A1 (en) * 2011-09-20 2014-08-14 National University Corporation Tokyo Medical And Dental University Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases
JP6216721B2 (ja) 2011-12-14 2017-10-18 アブラクシス バイオサイエンス， エルエルシー 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
PL3998069T3 (pl) 2015-06-29 2025-03-31 Abraxis Bioscience, Llc Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
JP7832108B2 (ja) 2019-10-28 2026-03-17 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
PT1585548T (pt) * 2002-12-09 2018-10-17 Abraxis Bioscience Llc Composições e métodos de administração de agentes farmacológicos
CN103405405A (zh) * 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US6825236B2 (en) * 2003-04-14 2004-11-30 California Pacific Medical Center Colchicine derivatives
ITMI20040164A1 (it) * 2004-02-03 2004-05-03 Indena Spa Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono
SI1853250T1 (sl) * 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008027055A1 *

Also Published As

Publication number Publication date
WO2008027055A1 (en) 2008-03-06
IL197276A0 (en) 2009-12-24
CA2662140A1 (en) 2008-03-06
AU2006347740A1 (en) 2008-03-06
CN101568332A (zh) 2009-10-28
MX2009002054A (es) 2009-05-01
BRPI0622006A2 (pt) 2011-12-20
JP2010502603A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
US20080280987A1 (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP2056812A1 (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2019202037B2 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
CA2902071C (en) Combination chemotherapy regimens using albumin/paclitaxel nanoparticles and nucleoside analogs
CA2680207C (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
RU2561055C2 (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
AU2007334360B2 (en) Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
ES2243744T3 (es) Inhibidores de integrina para el tratamiento de enfermedades de los ojos.
JP2021521173A (ja) 眼内薬物送達用の持続放出微粒子のための方法及び組成物
KR101644440B1 (ko) 개선된 혈관신생 억제용 펩티드와 이를 유효성분으로 함유하는 혈관신생과 관련된 질환의 예방 및 치료용 조성물
KR20090057074A (ko) 혈관형성 억제 및 혈관형성 관련 질환 치료 방법
Berillo et al. Review of recent advances in the use of drug delivery systems in ophthalmology
TW200810745A (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2013204181A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
ES2991634T3 (es) Vasodilatadores para su uso en el tratamiento de un trastorno isquémico de la retina
CA2917298C (en) Novel formulations of factor viia inhibitors and utility
US20190275001A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
KR20250073220A (ko) 신경망막 약물 전달을 위한 접합체
Alrbyawi Drug Delivery Devices for Cancer and Posterior Eye
HK1241281A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABRAXIS BIOSCIENCE, LLC

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120723

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121204